Hematology & Blood Cancer
Advertisement
Chemotherapy is the main treatment for leukemia, with the potential to increase patient survival to 5 years or longer.
The study explored if allogeneic HSCT to treat AML is equitably accessible regardless of social determinants of health.
Allogeneic HSCT has substantially improved outcomes for patients impacted by aggressive hematologic malignancies.
Josie Montegaard, NP, shares insights on how nurses can help patients manage their mental health during CLL treatment.
Josie Montegaard, NP, discusses key developments in the field of CLL and how they will innovate the treatment landscape.
The program evaluated the practicality of independent pharmacists and nurses monitoring patients on a targeted-based regimen.
According to a team of researchers from China, family resilience could hold the key to boosting quality of life.
Understanding the relationship between caregiver burden and patient hope is essential, according to the researchers.
A series of semi-structured interviews revealed a “unique and burdensome” symptom experience among these patients.
The nurse-led team of researchers evaluated health information seeking behaviors across socioeconomic status groups.
Josie Montegaard, NP, shares how nurses can help patients mitigate and manage negative CLL treatment side effects.
Researchers analyzed clinical outcomes because hematopoietic SCT is becoming more a more accessible and utilized treatment.
Research presented at the NCCN Annual Conference illuminated patient experiences with tyrosine kinase inhibitors.
Researchers assessed the cost effectiveness of ibrutinib, acalabrutinib, and zanubrutinib in multiple treatment settings.
Researchers investigated underlying drivers of HRQOL degradation in CLL, including muscle weakness and fatigue.
Amy Pierre, RN, BSN, ANP-BC, shares her insights on the importance of Multiple Myeloma Awareness Month.
Josie Montegaard, NP, discusses key guidelines, criteria, and the need for flexibility when initiating treatment for CLL.
Previous research showed a potential connection between obesity and moderate to severe GVHD post-allogeneic SCT.
Learn how ACCESS study data is informing patient-centered GVHD care and eliminating the donor access barrier for HSCT trials.
Josie Montegaard, NP, shares how the right treatment timing and approach can influence quality of life for patients with CLL.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.